Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cempra Pharmaceuticals and Biovista have signed a research agreement to systematically identify and profile adverse event associations for members of the macrolide drug class.
Subscribe to our email newsletter
The data generated will be used to better understand the unique benefit/risk characteristics of this important group of antimicrobial drugs, thereby helping to adapt and optimize future clinical trial designs, said Cempra.
Cempra’s macrolide in development, CEM-101, has recently completed a Phase I study.
In addition to its antibacterial programs, Cempra said that it is addressing non-antibiotic, therapeutic uses for macrolides and is screening its macrolide library for motilin-receptor activity, anti-inflammatory activity and GnRH receptor antagonism.
Prabha Fernandes, president and CEO of Cempra, said: “This collaboration with Biovista is a significant step forward in understanding macrolide safety profiles in a way that will help us further our clinical development plans, and ultimately further our goal to bring much-needed antimicrobial and therapeutic drugs to market.”